Synapse - Melissa Johnson

Results (19)

A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers

Journal Article

Li, B. T.; Drilon, A.; Johnson, M. L.; Hsu, M.; Sima, C. S.; McGinn, C.; Sugita, H.; Kris, M. G.; Azzoli, C. G.
Annals of Oncology (2016)

Fulltext@MSK | Save

Serum biomarkers associated with clinical outcomes fail to predict brain metastases in patients with stage IV non-small cell lung cancers

Journal Article

Li, B. T.; Lou, E.; Hsu, M.; Yu, H. A.; Naidoo, J.; Zauderer, M. G.; Sima, C.; Johnson, M. L.; Daras, M.; Deangelis, L. M.; more...
PLoS ONE (2016)

Fulltext@MSK | Save

Lungs don't forget: Comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers

Journal Article

Varghese, A. M.; Sima, C. S.; Chaft, J. E.; Johnson, M. L.; Riely, G. J.; Ladanyi, M.; Kris, M. G.
Journal of Thoracic Oncology (2013)

Fulltext@MSK | Save

Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: Higher susceptibility of women to smoking-related KRAS-mutant cancers

Journal Article

Dogan, S.; Shen, R.; Ang, D. C.; Johnson, M. L.; D'Angelo, S. P.; Paik, P. K.; Brzostowski, E. B.; Riely, G. J.; Kris, M. G.; Zakowski, M. F.; more...
Clinical Cancer Research (2012)

Fulltext@MSK | Save

Breast carcinoma with brain metastases: Clinical analysis and immunoprofile on tissue microarrays

Journal Article

Brogi, E.; Murphy, C. G.; Johnson, M. L.; Conlin, A. K.; Hsu, M.; Patil, S.; Akram, M.; Nehhozina, T.; Jhaveri, K. L.; Hudis, C. A.; more...
Annals of Oncology (2011)

Fulltext@MSK | Save

A phase II trial of salirasib in patients with lung adenocarcinomas with KRAS mutations

Journal Article

Riely, G. J.; Johnson, M. L.; Medina, C.; Rizvi, N. A.; Miller, V. A.; Kris, M. G.; Pietanza, M. C.; Azzoli, C. G.; Krug, L. M.; Pao, W.; more...
Journal of Thoracic Oncology (2011)

Fulltext@MSK | Save

Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib

Journal Article

Johnson, M. L.; Riely, G. J.; Rizvi, N. A.; Azzoli, C. G.; Kris, M. G.; Sima, C. S.; Ginsberg, M. S.; Pao, W.; Miller, V. A.
Journal of Thoracic Oncology (2011)

Fulltext@MSK | Save

Incidence of EGFR Exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas

Journal Article

D'Angelo, S. P.; Pietanza, M. C.; Johnson, M. L.; Riely, G. J.; Miller, V. A.; Sima, C. S.; Zakowski, M. F.; Rusch, V. W.; Ladanyi, M.; Kris, M. G.
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save

Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors